We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $677M
1-Year Est. Return 322.07%
This Fund
S&P 500
This Quarter Est. Return
+55.03%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$677M
AUM Growth
+$25.4M
Cap. Flow
-$22.1M
Cap. Flow %
-3.26%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
GENB
Generate Biomedicines
GENB
+$23.7M
2
LYEL icon
Lyell Immunopharma
LYEL
+$11.4M

Top Sells

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$46.9M
2
TXG icon
10x Genomics
TXG
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MAZE
1
Maze Therapeutics
MAZE
$1.53B
$123M 18.16%
4,120,053
– –
RAPP
2
Rapport Therapeutics
RAPP
$2.05B
$117M 17.23%
3,728,738
– –
VIR icon
3
Vir Biotechnology
VIR
$1.5B
$116M 17.09%
12,916,663
– –
ERAS icon
4
Erasca
ERAS
$6.48B
$115M 16.95%
7,091,557
-3,963,997
-36% -$46.9M
BEAM icon
5
Beam Therapeutics
BEAM
$2.73B
$108M 15.98%
4,540,132
– –
LYEL icon
6
Lyell Immunopharma
LYEL
$336M
$65.1M 9.62%
3,247,162
+488,090
+18% +$11.4M
GENB
7
Generate Biomedicines
GENB
$1.8B
$24.3M 3.59%
+1,944,426
New +$23.7M
TXG icon
8
10x Genomics
TXG
$6.28B
$4.62M 0.68%
217,834
-519,705
-70% -$10.4M
GOSS icon
9
Gossamer Bio
GOSS
$87.2M
$2.65M 0.39%
8,055,916
– –
QTTB icon
10
Q32 Bio
QTTB
$462M
$2.06M 0.3%
320,482
– –

Similar funds

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
NCM
Noesis Capital Mangement Boca Raton, Florida $676M AUM 34.17% 1-Year Est. Return
TWM
Topsail Wealth Management Charlotte, North Carolina $678M AUM 13.87% 1-Year Est. Return
DLIC
Daido Life Insurance Company Osaka, Japan $678M AUM 16.09% 1-Year Est. Return
REAM
Ripple Effect Asset Management New York $679M AUM 81.6% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Arch Venture Management's Q1 2026 Portfolio in Review

As of Q1 2026, Arch Venture Management held 10 positions worth $677M, up 3.9% from $652M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Arch Venture Management withdrew a net $22.1M in Q1 2026, reducing 2 holdings. Its largest reduction was Erasca, cutting an estimated $46.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Arch Venture Management opened a new position in Generate Biomedicines worth $24.3M.

  • Arch Venture Management's largest Q1 2026 buy was Generate Biomedicines: 1,944,426 shares worth $24.3M.
  • Arch Venture Management added most to Lyell Immunopharma in Q1 2026, an estimated $11.4M increase.
  • Arch Venture Management's biggest Q1 2026 reduction was Erasca, cutting an estimated $46.9M.
  • Arch Venture Management's ten largest holdings make up 100% of its $677M portfolio in Q1 2026.
  • Arch Venture Management opened 1 new position and closed 0 in Q1 2026.
  • Arch Venture Management's portfolio value rose 3.9% quarter-over-quarter to $677M.

Based on Arch Venture Management's 13F filing for Q1 2026, filed 15 May 2026.